Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -3.16% is 110% below its 5-year average of 31.69%, near the low end of its 5-year range (-3.16%–38.49%).
As of the fiscal period ended Tuesday, June 30, 2026. 120.52% below its 12-month average of 15.38%.
Reported quarterly EBITDA margin; no daily interpolation.
EBITDA MARGIN
-3.16%
EBITDA MARGIN AVG TTM
15.38%
EBITDA MARGIN AVG 3Y
28.25%
EBITDA MARGIN AVG 5Y
31.69%
EBITDA MARGIN AVG 10Y
33.61%
EBITDA MARGIN AVG 15Y
32.92%
EBITDA MARGIN AVG 20Y
31.83%
CURRENT VS TTM AVG
-120.52%
CURRENT VS 3Y AVG
-111.17%
CURRENT VS 5Y AVG
-109.96%
CURRENT VS 10Y AVG
-109.39%
CURRENT VS 15Y AVG
-109.59%
CURRENT VS 20Y AVG
-109.92%
Market Cap
$407.09M
EBITDA Margin
-48.80%
TTM Avg
-44.09%
3Y Avg
-45.35%
5Y Avg
-45.35%
Market Cap
$1.24B
EBITDA Margin
3.96%
TTM Avg
-13.21%
3Y Avg
-146.19%
5Y Avg
-104.68%
Market Cap
$2.33B
EBITDA Margin
16.41%
TTM Avg
1.22%
3Y Avg
-1.65%
5Y Avg
4.31%
Market Cap
$3.09B
EBITDA Margin
22.42%
TTM Avg
17.70%
3Y Avg
-0.76%
5Y Avg
-37.34%
Market Cap
$6.81B
EBITDA Margin
6.82%
TTM Avg
6.08%
3Y Avg
-0.44%
5Y Avg
-8.67%
Market Cap
$7.25B
EBITDA Margin
-3.14%
TTM Avg
-1.08%
3Y Avg
-5.02%
5Y Avg
-19.32%
Market Cap
$9.59B
EBITDA Margin
18.42%
TTM Avg
17.41%
3Y Avg
19.12%
5Y Avg
20.05%
Market Cap
$9.76B
EBITDA Margin
-11.84%
TTM Avg
-53.07%
3Y Avg
-52.51%
5Y Avg
-64.32%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NRC Health (NRC) | $481.83M | -3.16% | 15.38% | 28.25% | 31.69% |
| Shoulder Innovations, Inc. (SI)vs › | $407.09M | -48.80% | -44.09% | -45.35% | -45.35% |
| Teladoc Health, Inc. (TDOC)vs › | $1.24B | 3.96% | -13.21% | -146.19% | -104.68% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.33B | 16.41% | 1.22% | -1.65% | 4.31% |
| TransMedics Group, Inc. (TMDX)vs › | $3.09B | 22.42% | 17.70% | -0.76% | -37.34% |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.81B | 6.82% | 6.08% | -0.44% | -8.67% |
| Oscar Health, Inc. (OSCR)vs › | $7.25B | -3.14% | -1.08% | -5.02% | -19.32% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $9.59B | 18.42% | 17.41% | 19.12% | 20.05% |
| Tempus AI, Inc. (TEM)vs › | $9.76B | -11.84% | -53.07% | -52.51% | -64.32% |
| Insulet Corp. (PODD)vs › | $10.02B | 21.67% | 20.24% | 16.36% | 15.66% |
Gross Margin
56.3%
EBITDA Margin
-3.2%
Operating Margin
10.5%
Net Margin
4.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -3.16% |
| 2026-03-31 | 22.23% |
| 2025-12-31 | 19.36% |
| 2025-09-30 | 28.70% |
| 2025-06-30 | 9.78% |
| 2025-03-31 | 30.22% |
| 2024-12-31 | 30.09% |
| 2024-09-30 | 26.59% |
| 2024-06-30 | 29.63% |
| 2024-03-31 | 28.90% |
| 2023-12-31 | 34.58% |
| 2023-09-30 | 30.33% |
| 2023-06-30 | 30.10% |
| 2023-03-31 | 28.54% |
| 2022-12-31 | 35.70% |
| 2022-09-30 | 32.91% |
| 2022-06-30 | 34.29% |
| 2022-03-31 | 33.85% |
| 2021-12-31 | 37.16% |
| 2021-09-30 | 38.49% |
| 2021-06-30 | 38.09% |
| 2021-03-31 | 39.49% |
| 2020-12-31 | 37.58% |
| 2020-09-30 | 41.42% |
| 2020-06-30 | 34.27% |
| 2020-03-31 | 37.11% |
| 2019-12-31 | 40.51% |
| 2019-09-30 | 35.88% |
| 2019-06-30 | 36.89% |
| 2019-03-31 | 38.50% |
| 2018-12-31 | 35.45% |
| 2018-09-30 | 35.16% |
| 2018-06-30 | 32.41% |
| 2018-03-31 | 33.02% |
| 2017-12-31 | 33.01% |
| 2017-09-30 | 28.51% |
| 2017-06-30 | 33.73% |
| 2017-03-31 | 36.63% |
| 2016-12-31 | 34.94% |
| 2016-09-30 | 31.17% |
| 2016-06-30 | 31.06% |
| 2016-03-31 | 32.20% |
| 2015-12-31 | 33.02% |
| 2015-09-30 | 30.18% |
| 2015-06-30 | 30.20% |
| 2015-03-31 | 26.05% |
| 2014-12-31 | 29.51% |
| 2014-09-30 | 34.24% |
| 2014-06-30 | 30.18% |
| 2014-03-31 | 35.86% |
| 2013-12-31 | 30.41% |
| 2013-09-30 | 30.95% |
| 2013-06-30 | 28.93% |
| 2013-03-31 | 32.79% |
| 2012-12-31 | 31.22% |
| 2012-09-30 | 31.78% |
| 2012-06-30 | 31.17% |
| 2012-03-31 | 32.69% |
| 2011-12-31 | 32.89% |
| 2011-09-30 | 29.68% |
| 2011-06-30 | 27.66% |
| 2011-03-31 | 35.08% |
| 2010-12-31 | 23.18% |
| 2010-09-30 | 29.48% |
| 2010-06-30 | 26.29% |
| 2010-03-31 | 37.10% |
| 2009-12-31 | 30.73% |
| 2009-09-30 | 31.06% |
| 2009-06-30 | 26.43% |
| 2009-03-31 | 32.76% |
| 2008-12-31 | 29.99% |
| 2008-09-30 | 28.34% |
| 2008-06-30 | 27.17% |
| 2008-03-31 | 29.49% |
| 2007-12-31 | 22.93% |
| 2007-09-30 | 34.27% |
| 2007-06-30 | 27.87% |
| 2007-03-31 | 27.50% |
| 2006-12-31 | 24.85% |
| 2006-09-30 | 34.49% |
| 2006-06-30 | 24.77% |
| 2006-03-31 | 25.01% |
| 2005-12-31 | 32.07% |
| 2005-09-30 | 37.34% |
| 2005-06-30 | 27.80% |
| 2005-03-31 | 25.19% |
| 2004-12-31 | 30.07% |
| 2004-09-30 | 35.64% |
| 2004-06-30 | 28.33% |
| 2004-03-31 | 31.20% |
| 2003-12-31 | 35.41% |
| 2003-09-30 | 32.93% |
| 2003-06-30 | 31.46% |
| 2003-03-31 | 32.32% |
| 2002-12-31 | 39.42% |
| 2002-09-30 | 37.29% |
